首页> 外文期刊>Gastroenterology Research >Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment
【24h】

Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment

机译:胆管癌发病机理中的分子标记:早期发现和适当治疗选择的潜力。

获取原文
           

摘要

Cholangiocarcinoma (CC) is a primary malignancy that arises from cholangiocytes, the epithelial cells lining the bile duct livers. The worldwide incidence of CC is increasing and despite of combined therapeutic strategies, its prognosis remains poor. Till now surgery remains the only curative treatment modality. Over the past years, several important studies have yielded new insights into the molecular mechanisms of cholangiocarcinoma. This review focused on critical molecular player during the development from inflammation and cellular and molecular pathogenesis of this disease. The novel prophylactic and therapeutic approach deals especially the molecules involved in inflammation of cholangiocite or those related to promotion and progression of CC. The elucidation of their specific effects and interaction of this complex mechanism will accelerate the development of new biomarker for early detection and predictor factors outcome in CC.
机译:胆管癌(CC)是原发性恶性肿瘤,由胆管细胞(胆管肝内衬的上皮细胞)引起。 CC的全球发病率正在增加,尽管采取了多种治疗策略,但其预后仍然很差。到目前为止,手术仍然是唯一的治疗方法。在过去的几年中,一些重要的研究对胆管癌的分子机制产生了新的见解。这篇综述着重于该疾病的炎症以及细胞和分子发病机理发展过程中的关键分子参与者。新颖的预防和治疗方法尤其涉及与胆管钙石的炎症有关的分子或与CC的促进和发展有关的分子。阐明它们的特殊作用和这种复杂机制的相互作用将加速CC中早期检测和预测因子结果的新生物标志物的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号